CRIS Current Research Information System

BACCARANI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.985
AS - Asia 23.613
EU - Europa 20.650
AF - Africa 1.487
SA - Sud America 1.373
Continente sconosciuto - Info sul continente non disponibili 75
OC - Oceania 34
Totale 77.217
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.716
VN - Vietnam 6.384
CN - Cina 6.236
SG - Singapore 6.190
GB - Regno Unito 5.919
SE - Svezia 3.107
DE - Germania 2.548
IT - Italia 2.368
HK - Hong Kong 1.436
FR - Francia 1.378
IN - India 1.214
RU - Federazione Russa 1.125
UA - Ucraina 1.048
BR - Brasile 974
IE - Irlanda 730
NL - Olanda 615
JP - Giappone 535
ZA - Sudafrica 473
EE - Estonia 391
TG - Togo 370
FI - Finlandia 316
KR - Corea 302
CH - Svizzera 269
CI - Costa d'Avorio 218
JO - Giordania 209
AR - Argentina 176
BG - Bulgaria 173
CA - Canada 169
SC - Seychelles 140
NG - Nigeria 129
BD - Bangladesh 128
BE - Belgio 127
PH - Filippine 125
TR - Turchia 121
IR - Iran 100
GR - Grecia 93
PL - Polonia 93
TH - Thailandia 87
AT - Austria 84
ID - Indonesia 80
HR - Croazia 77
IQ - Iraq 76
EC - Ecuador 70
EU - Europa 66
TW - Taiwan 66
MX - Messico 63
ES - Italia 54
SA - Arabia Saudita 54
UZ - Uzbekistan 50
PK - Pakistan 41
LB - Libano 39
CO - Colombia 36
MY - Malesia 36
CL - Cile 33
PY - Paraguay 30
RO - Romania 28
AU - Australia 27
CZ - Repubblica Ceca 25
KE - Kenya 25
VE - Venezuela 25
EG - Egitto 23
TN - Tunisia 22
MA - Marocco 21
ET - Etiopia 20
AE - Emirati Arabi Uniti 19
LT - Lituania 17
IL - Israele 16
DZ - Algeria 13
PE - Perù 13
AL - Albania 10
NP - Nepal 10
RS - Serbia 10
A2 - ???statistics.table.value.countryCode.A2??? 7
BO - Bolivia 7
DO - Repubblica Dominicana 7
KZ - Kazakistan 7
OM - Oman 7
QA - Qatar 7
HN - Honduras 6
PT - Portogallo 6
AZ - Azerbaigian 5
BA - Bosnia-Erzegovina 5
BY - Bielorussia 5
CR - Costa Rica 5
DK - Danimarca 5
GE - Georgia 5
KG - Kirghizistan 5
NO - Norvegia 5
PS - Palestinian Territory 5
SK - Slovacchia (Repubblica Slovacca) 5
UY - Uruguay 5
MK - Macedonia 4
NZ - Nuova Zelanda 4
PA - Panama 4
SY - Repubblica araba siriana 4
AO - Angola 3
BS - Bahamas 3
GT - Guatemala 3
GY - Guiana 3
HU - Ungheria 3
Totale 77.151
Salva come PNG Salva come JPEG
Città #
Southend 5.272
Singapore 4.129
Fairfield 3.338
Ashburn 2.866
Chandler 2.417
Woodbridge 1.753
Houston 1.577
Seattle 1.564
Wilmington 1.536
Hong Kong 1.361
Dong Ket 1.340
San Jose 1.307
Cambridge 1.207
Ho Chi Minh City 1.206
Ann Arbor 1.200
Princeton 1.073
Hanoi 974
Beijing 951
Santa Clara 853
Dublin 723
Hefei 681
Boardman 662
Jacksonville 632
Nanjing 541
Lauterbourg 515
Westminster 470
Padova 462
Tokyo 436
Lomé 369
Los Angeles 359
New York 334
Bologna 322
Helsinki 283
Berlin 272
Jinan 253
Buffalo 239
Seoul 238
Saint Petersburg 237
Shenyang 227
Dallas 223
Abidjan 217
Bern 215
Amman 208
San Diego 198
Turin 198
Milan 196
Changsha 177
Sofia 170
Bremen 166
Hebei 166
Nanchang 161
Haiphong 158
Frankfurt am Main 150
Da Nang 145
Medford 133
Redondo Beach 131
Guangzhou 127
São Paulo 120
Brussels 117
Jiaxing 117
Tianjin 117
Munich 113
Mülheim 111
Zhengzhou 111
Redmond 107
Abeokuta 105
Florence 104
Shanghai 99
Redwood City 98
Falls Church 87
Hangzhou 82
Norwalk 80
London 77
Haikou 76
Orem 73
Mahé 72
Rome 72
Council Bluffs 71
Des Moines 70
The Dalles 68
Toronto 67
Can Tho 65
Dearborn 64
Ningbo 60
Chicago 59
Falkenstein 59
Taiyuan 59
Taizhou 59
Warsaw 59
Phoenix 58
Biên Hòa 57
Bengaluru 56
Hải Dương 55
Istanbul 52
Wuhan 52
Yubileyny 51
Verona 49
Olalla 48
Chengdu 46
Baghdad 44
Totale 50.584
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 385
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. 341
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 341
18F-FDG PET early after radiotherapy in lymphoma patients. 315
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 315
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 308
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 302
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 299
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 289
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 283
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 283
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 279
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 273
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 271
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 267
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 264
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 260
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 252
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 252
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 251
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 251
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 250
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 250
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 249
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 246
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 244
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 242
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 241
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 239
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 235
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 233
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 232
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 228
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 228
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 226
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 225
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 224
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 224
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 223
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 223
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 222
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 221
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 221
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 220
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 220
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 218
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 218
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 217
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 217
Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of acute graft-versus-host disease in allogeneic stem cell transplantation from related donors. 217
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in complete hematologic remission. 216
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 216
Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. 215
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 214
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 214
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 213
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 212
Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. 211
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 210
Advances in the treatment for haematological malignancies. 210
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 210
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 209
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 209
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 209
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 208
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 208
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 208
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 207
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 207
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 207
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 206
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 206
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 206
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 206
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 205
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 203
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 201
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 201
Ascorbic acid inhibits antitumor activity of bortezomib in vivo 201
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 201
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 200
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 200
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 199
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia 199
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 199
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 198
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. 198
CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571 198
Developing a new grading system of ocular surface disease after allogeneic hematopoietic stem cell transplantation (HSCT). 197
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 197
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 196
Immune therapy of chronic myelogenous leukemia. 195
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 195
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 194
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 193
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 193
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 192
Totale 23.101
Salva come PNG Salva come JPEG
Categoria #
all - tutte 202.997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 202.997
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.381 0 0 0 0 0 0 0 0 0 432 467 2.482
2021/20229.676 1.049 266 732 966 913 622 191 620 358 759 1.637 1.563
2022/202310.230 1.238 1.565 583 1.336 673 816 370 532 1.615 235 808 459
2023/20242.524 151 423 151 247 208 599 152 134 87 153 97 122
2024/20259.165 274 1.609 770 686 1.459 482 760 192 66 811 236 1.820
2025/202619.414 1.394 2.172 2.131 1.383 2.534 1.396 1.833 984 4.207 1.380 0 0
Totale 78.489